-
1
-
-
0032511583
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
-
UK Prospective Diabetes Study (UKPDS) Group
-
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
-
(1998)
Lancet
, vol.352
, pp. 837-853
-
-
-
2
-
-
0027370108
-
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
-
The Diabetes Control and Complications Trial ResearchGroup
-
The Diabetes Control and Complications Trial ResearchGroup. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
-
(1993)
N Engl J Med
, vol.329
, pp. 977-986
-
-
-
3
-
-
0032958316
-
Design and implementation of a long-term follow-up of the Diabetes Control and Complications Trial cohort
-
Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC)
-
Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC). Design and implementation of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99-111
-
(1999)
Diabetes Care
, vol.22
, pp. 99-111
-
-
-
4
-
-
77649329576
-
Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
-
Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010;362:800-811
-
(2010)
N Engl J Med
, vol.362
, pp. 800-811
-
-
Selvin, E.1
Steffes, M.W.2
Zhu, H.3
-
5
-
-
78650345164
-
Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes
-
Selvin E, Ning Y, Steffes MW, et al. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes 2011;60:298-305
-
(2011)
Diabetes
, vol.60
, pp. 298-305
-
-
Selvin, E.1
Ning, Y.2
Steffes, M.W.3
-
6
-
-
84919999219
-
Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach
-
Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
-
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149
-
(2015)
Diabetes Care
, vol.38
, pp. 140-149
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
7
-
-
84906978168
-
-
Centers for Disease Control and Prevention. Atlanta, GA, U. S. Department of Health and Human Services. Accessed 10 January 2016
-
Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2014 [Internet], 2014. Atlanta, GA, U. S. Department of Health and Human Services. Available fromhttp://www. cdc. gov/diabetes/pubs/statsreport14/ national-diabetes-report-web. pdf. Accessed 10 January 2016
-
(2014)
National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014 [Internet]
-
-
-
8
-
-
84876550739
-
Achievement of goals in U. S. Diabetes care, 1999-2010
-
Ali MK, Bullard KM, Saaddine JB, Cowie CC, Imperatore G, Gregg EW. Achievement of goals in U. S. diabetes care, 1999-2010. N Engl J Med 2013;368:1613-1624
-
(2013)
N Engl J Med
, vol.368
, pp. 1613-1624
-
-
Ali, M.K.1
Bullard, K.M.2
Saaddine, J.B.3
Cowie, C.C.4
Imperatore, G.5
Gregg, E.W.6
-
9
-
-
85033211667
-
Achievement of glycated hemoglobin goals in the U. S. Remains unchanged through 2014. Poster (1515-P)
-
10-14 June 2016, New Orleans, LA
-
Carls GS, Huynh J, Tuttle E, Edelman SV. Achievement of glycated hemoglobin goals in the U. S. remains unchanged through 2014. Poster (1515-P) presented at the 76th Scientific Sessions of the American Diabetes Association, 10-14 June 2016, New Orleans, LA
-
The 76th Scientific Sessions of the American Diabetes Association
-
-
Carls, G.S.1
Huynh, J.2
Tuttle, E.3
Edelman, S.V.4
-
10
-
-
84988575514
-
-
National Committee for Quality Assurance. Washington, DC, National Committee for Quality Assurance. Accessed 5 July 2016
-
National Committee for Quality Assurance. The State of Health Care Quality Report 2015 [Internet], 2015. Washington, DC, National Committee for Quality Assurance. Available for download from http://store. ncqa. org/index. php/catalog/ product/view/id/2341/s/2015-state-of-healthcare-quality-report/. Accessed 5 July 2016
-
(2015)
The State of Health Care Quality Report 2015 [Internet]
-
-
-
11
-
-
85033229775
-
-
Centers for Disease Control and Prevention. Accessed 8 September 2017
-
Centers for Disease Control and Prevention. PowerPoint slides on diabetes: Long-term trends in diabetes [Internet], 2017. Available from https://www. cdc. gov/diabetes/data/center/ slides. html. Accessed 8 September 2017
-
(2017)
PowerPoint Slides on Diabetes: Long-term Trends in Diabetes [Internet]
-
-
-
12
-
-
77951700065
-
-
U. S. Food andDrug Administration. Accessed 12 July 2016
-
U. S. Food andDrug Administration. DrugsFDA: FDA approved drug products [Internet]. Available from https://www. Accessdata. fda. gov/scripts/ cder/drugsatfda/. Accessed 12 July 2016
-
DrugsFDA: FDA Approved Drug Products [Internet]
-
-
-
14
-
-
80053569496
-
Participation in a clinical trial enhances adherence and persistence to treatment: A retrospective cohort study
-
van Onzenoort HA, Menger FE, Neef C, et al. Participation in a clinical trial enhances adherence and persistence to treatment: A retrospective cohort study. Hypertension 2011;58:573-578
-
(2011)
Hypertension
, vol.58
, pp. 573-578
-
-
Van Onzenoort, H.A.1
Menger, F.E.2
Neef, C.3
-
15
-
-
11444261579
-
External validity of randomised controlled trials: To whom do the results of this trial apply
-
Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply" Lancet 2005;365:82-93
-
(2005)
Lancet
, vol.365
, pp. 82-93
-
-
Rothwell, P.M.1
-
16
-
-
85033230434
-
-
National Heart, Lung, and Blood Institute. Accessed 8 September 2017
-
National Heart, Lung, and Blood Institute. What are the possible benefits and risks of clinical trials [Internet], 2017. Available from https://www. nhlbi. nih. gov/studies/clinicaltrials/benefitsrisks. Accessed 8 September 2017
-
(2017)
What Are the Possible Benefits and Risks of Clinical Trials. [Internet]
-
-
-
17
-
-
85033221796
-
-
Harvard Women's HealthWatch, July Accessed 23 July 2016
-
Harvard Women's HealthWatch. What clinical studies can do for you [Internet], July 2012. Available from http://www. health. harvard. edu/ staying-healthy/what-clinical-studies-can-do-foryou. Accessed 23 July 2016
-
(2012)
What Clinical Studies Can Do for You [Internet]
-
-
-
18
-
-
69949088253
-
Patients' motivations for participating in cardiovascular clinical trials: A local perspective
-
Burgess LJ, Sulzer NU, Hoosain F, Leverton N, Bliganut S, Emanuel S. Patients' motivations for participating in cardiovascular clinical trials: A local perspective. Cardiovasc J Afr 2009;20: 220-223
-
(2009)
Cardiovasc J Afr
, vol.20
, pp. 220-223
-
-
Burgess, L.J.1
Sulzer, N.U.2
Hoosain, F.3
Leverton, N.4
Bliganut, S.5
Emanuel, S.6
-
19
-
-
34247589078
-
Patient adherence tomedical treatment: A review of reviews
-
van Dulmen S, Sluijs E, van Dijk L, de Ridder D, Heerdink R, Bensing J. Patient adherence tomedical treatment: A review of reviews. BMC Health Serv Res 2007;7:55-67
-
(2007)
BMC Health Serv Res
, vol.7
, pp. 55-67
-
-
Van Dulmen, S.1
Sluijs, E.2
Van Dijk, L.3
De Ridder, D.4
Heerdink, R.5
Bensing, J.6
-
20
-
-
41549105366
-
Factors affecting therapeutic compliance: A review from the patient's perspective
-
Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient's perspective. Ther Clin Risk Manag 2008;4:269-286
-
(2008)
Ther Clin Risk Manag
, vol.4
, pp. 269-286
-
-
Jin, J.1
Sklar, G.E.2
Min Sen Oh, V.3
Chuen Li, S.4
-
21
-
-
85033228169
-
Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes
-
Carls GS, Tuttle E, Tan R-D, et al. Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes. Diabetes Care 2017;40:1469-1478
-
(2017)
Diabetes Care
, vol.40
, pp. 1469-1478
-
-
Carls, G.S.1
Tuttle, E.2
Tan, R.-D.3
-
22
-
-
77952309372
-
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial
-
1860-LIRA-DPP-4 Study Group
-
Pratley RE, Nauck M, Bailey T, et al.; 1860-LIRA-DPP-4 Study Group. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: A 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-1456
-
(2010)
Lancet
, vol.375
, pp. 1447-1456
-
-
Pratley, R.E.1
Nauck, M.2
Bailey, T.3
-
23
-
-
62449129181
-
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)
-
LEAD-1 SU study group
-
Marre M, Shaw J, Brändle M, et al.; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-278
-
(2009)
Diabet Med
, vol.26
, pp. 268-278
-
-
Marre, M.1
Shaw, J.2
Brändle, M.3
-
24
-
-
62449169287
-
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
-
LEAD-2 Study Group
-
NauckM, Frid A, Hermansen K, et al.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009;32:84-90
-
(2009)
Diabetes Care
, vol.32
, pp. 84-90
-
-
Nauck, M.1
Frid, A.2
Hermansen, K.3
-
25
-
-
77953859640
-
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial
-
DiamantM, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): An open-label randomised trial. Lancet 2010;375:2234-2243
-
(2010)
Lancet
, vol.375
, pp. 2234-2243
-
-
Diamant, M.1
Van Gaal, L.2
Stranks, S.3
-
26
-
-
79955661908
-
DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes
-
Blevins T, Pullman J, Malloy J, et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011;96:1301-1310
-
(2011)
J Clin Endocrinol Metab
, vol.96
, pp. 1301-1310
-
-
Blevins, T.1
Pullman, J.2
Malloy, J.3
-
27
-
-
59449101432
-
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, doubleblind, parallel-treatment trial
-
LEAD-3 (Mono) Study Group
-
Garber A, Henry R, Ratner R, et al.; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, doubleblind, parallel-treatment trial. Lancet 2009;373: 473-481
-
(2009)
Lancet
, vol.373
, pp. 473-481
-
-
Garber, A.1
Henry, R.2
Ratner, R.3
-
28
-
-
67650066860
-
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)
-
LEAD-4 Study Investigators
-
Zinman B, Gerich J, Buse JB, et al.; LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-1230
-
(2009)
Diabetes Care
, vol.32
, pp. 1224-1230
-
-
Zinman, B.1
Gerich, J.2
Buse, J.B.3
-
29
-
-
33846817233
-
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patientswith type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial
-
Sitagliptin Study 024 Group
-
Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patientswith type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007;9:194-205
-
(2007)
Diabetes Obes Metab
, vol.9
, pp. 194-205
-
-
Nauck, M.A.1
Meininger, G.2
Sheng, D.3
Terranella, L.4
Stein, P.P.5
-
30
-
-
69549135336
-
The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone
-
Saxagliptin 014 Study Group
-
DeFronzo RA, Hissa MN, Garber AJ, et al.; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009;32:1649-1655
-
(2009)
Diabetes Care
, vol.32
, pp. 1649-1655
-
-
DeFronzo, R.A.1
Hissa, M.N.2
Garber, A.J.3
-
31
-
-
78650656671
-
Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: A randomized, double-blind, non-inferiority trial
-
Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2011;13:160-168
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 160-168
-
-
Arechavaleta, R.1
Seck, T.2
Chen, Y.3
-
32
-
-
78349292168
-
Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: A 52-week randomised controlled trial
-
D1680C00001 Investigators
-
Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I; D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: A 52-week randomised controlled trial. Int J Clin Pract 2010;64:1619-1631
-
(2010)
Int J Clin Pract
, vol.64
, pp. 1619-1631
-
-
Göke, B.1
Gallwitz, B.2
Eriksson, J.3
Hellqvist, A.4
Gause-Nilsson, I.5
-
33
-
-
84862152967
-
Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: Meta-analysis and systematic review
-
Aroda VR, Henry RR, Han J, et al. Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clin Ther 2012;34:1247-1258. e22
-
(2012)
Clin Ther
, vol.34
, pp. 1247-1258e22
-
-
Aroda, V.R.1
Henry, R.R.2
Han, J.3
-
34
-
-
85033227233
-
-
Centers for Medicare & Medicaid Services. Accessed 22 November 2016
-
Centers for Medicare & Medicaid Services. Medicare 2016 Part C & D star rating technical notes (draft) [Internet], 2015. Available from https://www. cms. gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/ Downloads/2016-Technical-Notes-Preview-1-v2015-08-05. pdf. Accessed 22 November 2016
-
(2015)
Medicare 2016 Part C & D Star Rating Technical Notes (Draft) [Internet]
-
-
-
35
-
-
64549094715
-
Diabetic patients' medication underuse, illness outcomes, and beliefs about antihyperglycemic and antihypertensive treatments
-
Aikens JE, Piette JD. Diabetic patients' medication underuse, illness outcomes, and beliefs about antihyperglycemic and antihypertensive treatments. Diabetes Care 2009;32:19-24
-
(2009)
Diabetes Care
, vol.32
, pp. 19-24
-
-
Aikens, J.E.1
Piette, J.D.2
-
36
-
-
84919845727
-
Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus
-
Farr AM, Sheehan JJ, Curkendall SM, Smith DM, Johnston SS, Kalsekar I. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus. Adv Ther 2014;31:1287-1305
-
(2014)
Adv Ther
, vol.31
, pp. 1287-1305
-
-
Farr, A.M.1
Sheehan, J.J.2
Curkendall, S.M.3
Smith, D.M.4
Johnston, S.S.5
Kalsekar, I.6
-
37
-
-
84936928911
-
Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: A retrospective cohort study
-
Buysman EK, Liu F, Hammer M, Langer J. Impact of medication adherence and persistence on clinical and economic outcomes in patients with type 2 diabetes treated with liraglutide: A retrospective cohort study. Adv Ther 2015;32: 341-355
-
(2015)
Adv Ther
, vol.32
, pp. 341-355
-
-
Buysman, E.K.1
Liu, F.2
Hammer, M.3
Langer, J.4
-
38
-
-
85033232981
-
Treatment utilization patterns of GLP-1 agonists and DPP-4 inhibitors among type 2 diabetics in a U.S. Commercially insured population: 2005-2011. Poster (1589-P
-
21-25 June 2013, Chicago, IL
-
Koro CE, Chhabra P, Stender M, Spain CV, Allen JK, Krzywy HJ. Treatment utilization patterns of GLP-1 agonists and DPP-4 inhibitors among type 2 diabetics in a U. S. commercially insured population: 2005-2011. Poster (1589-P) presented at the 73rd Scientific Sessions of the American Diabetes Association, 21-25 June 2013, Chicago, IL
-
The 73rd Scientific Sessions of the American Diabetes Association
-
-
Koro, C.E.1
Chhabra, P.2
Stender, M.3
Spain, C.V.4
Allen, J.K.5
Krzywy, H.J.6
-
39
-
-
38549098101
-
Medication compliance and persistence: Terminology and definitions
-
Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: Terminology and definitions. Value Health 2008;11:44-47
-
(2008)
Value Health
, vol.11
, pp. 44-47
-
-
Cramer, J.A.1
Roy, A.2
Burrell, A.3
-
40
-
-
85033228497
-
Comparative persistence with antihyperglycemic agents used to treat type 2 diabetes mellitus in the real world
-
10-14 June 2016, New Orleans, LA
-
Cai J, Wang Y, Baser O, et al. Comparative persistence with antihyperglycemic agents used to treat type 2 diabetes mellitus in the real world. Poster (1155-P) presented at the 76th Scientific Sessions of the American Diabetes Association, 10-14 June 2016, New Orleans, LA
-
76th Scientific Sessions of the American Diabetes Association
-
-
Cai, J.1
Wang, Y.2
Baser, O.3
-
41
-
-
77951102841
-
Primary medication non-adherence: Analysis of 195, 930 electronic prescriptions
-
Fischer MA, Stedman MR, Lii J, et al. Primary medication non-adherence: Analysis of 195, 930 electronic prescriptions. J Gen Intern Med 2010; 25:284-290
-
(2010)
J Gen Intern Med
, vol.25
, pp. 284-290
-
-
Fischer, M.A.1
Stedman, M.R.2
Lii, J.3
-
42
-
-
33749006625
-
Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus
-
Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166: 1836-1841
-
(2006)
Arch Intern Med
, vol.166
, pp. 1836-1841
-
-
Ho, P.M.1
Rumsfeld, J.S.2
Masoudi, F.A.3
-
43
-
-
20544460816
-
Impact of medication adherence on hospitalization risk and healthcare cost
-
Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005;43:521-530
-
(2005)
Med Care
, vol.43
, pp. 521-530
-
-
Sokol, M.C.1
McGuigan, K.A.2
Verbrugge, R.R.3
Epstein, R.S.4
-
45
-
-
84984991360
-
Associations between adherence and outcomes among older, type 2 diabetes patients: Evidence from a Medicare Supplemental database
-
Boye KS, Curtis SE, Lage MJ, Garcia-Perez LE. Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database. Patient Prefer Adherence 2016;10:1573-1581
-
(2016)
Patient Prefer Adherence
, vol.10
, pp. 1573-1581
-
-
Boye, K.S.1
Curtis, S.E.2
Lage, M.J.3
Garcia-Perez, L.E.4
-
46
-
-
84978839381
-
Liraglutide and cardiovascular outcomes in type 2 diabetes
-
LEADER Steering Committee; LEADER Trial Investigators
-
Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl JMed 2016;375: 311-322
-
(2016)
N Engl JMed
, vol.375
, pp. 311-322
-
-
Marso, S.P.1
Daniels, G.H.2
Brown-Frandsen, K.3
-
47
-
-
85033241313
-
Novo Nordisk drug cuts diabetic deaths, but not enough for Wall Street [article online]
-
14 June. Accessed 18 July 2016
-
Reeves A. Novo Nordisk drug cuts diabetic deaths, but not enough for Wall Street [article online]. Investor's Business Daily, 14 June 2016. Available from http://www. investors. com/news/ technology/novo-nordisk-drug-cuts-diabeticdeaths-but-not-enough-for-street/. Accessed 18 July 2016
-
(2016)
Investor's Business Daily
-
-
Reeves, A.1
-
48
-
-
84891805411
-
Adherence to therapies in patients with type 2 diabetes
-
Garca-Pérez LE, AlvarezM, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther 2013;4:175-194
-
(2013)
Diabetes Ther
, vol.4
, pp. 175-194
-
-
Garca-Pérez, L.E.1
Alvarez, M.2
Dilla, T.3
Gil-Guillén, V.4
Orozco-Beltrán, D.5
-
49
-
-
0036361575
-
Physicianpatient communication in the primary care office: A systematic review
-
Beck RS, Daughtridge R, Sloane PD. Physicianpatient communication in the primary care office: A systematic review. J Am Board Fam Pract 2002; 15:25-38
-
(2002)
J Am Board Fam Pract
, vol.15
, pp. 25-38
-
-
Beck, R.S.1
Daughtridge, R.2
Sloane, P.D.3
-
50
-
-
68249138773
-
Physician communication and patient adherence to treatment: A meta-analysis
-
Zolnierek KB, Dimatteo MR. Physician communication and patient adherence to treatment: A meta-analysis. Med Care 2009;47:826-834
-
(2009)
Med Care
, vol.47
, pp. 826-834
-
-
Zolnierek, K.B.1
Dimatteo, M.R.2
-
51
-
-
70449677664
-
Cost-related nonadherence to medications among patients with diabetes and chronic pain: Factors beyond finances
-
Kurlander JE, Kerr EA, Krein S, Heisler M, Piette JD. Cost-related nonadherence to medications among patients with diabetes and chronic pain: factors beyond finances. Diabetes Care 2009;32:2143-2148
-
(2009)
Diabetes Care
, vol.32
, pp. 2143-2148
-
-
Kurlander, J.E.1
Kerr, E.A.2
Krein, S.3
Heisler, M.4
Piette, J.D.5
-
52
-
-
84868309875
-
Rethinking adherence
-
Steiner JF. Rethinking adherence. Ann Intern Med 2012;157:580-585
-
(2012)
Ann Intern Med
, vol.157
, pp. 580-585
-
-
Steiner, J.F.1
-
53
-
-
84923366744
-
A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetesdimpact on adherence
-
Sapkota S, Brien JA, Greenfield J, Aslani P. A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetesdimpact on adherence. PLoS One 2015;10:e0118296
-
(2015)
PLoS One
, vol.10
, pp. e0118296
-
-
Sapkota, S.1
Brien, J.A.2
Greenfield, J.3
Aslani, P.4
-
54
-
-
84855670216
-
An integrated pharmacy-based program improved medication prescription and adherence rates in diabetes patients
-
Brennan TA, Dollear TJ, Hu M, et al. An integrated pharmacy-based program improved medication prescription and adherence rates in diabetes patients. Health Aff (Millwood) 2012; 31:120-129
-
(2012)
Health Aff (Millwood)
, vol.31
, pp. 120-129
-
-
Brennan, T.A.1
Dollear, T.J.2
Hu, M.3
-
55
-
-
79957610344
-
Effectiveness of home telehealth in comorbid diabetes and hypertension: A randomized, controlled trial
-
Wakefield BJ, Holman JE, Ray A, et al. Effectiveness of home telehealth in comorbid diabetes and hypertension: A randomized, controlled trial. Telemed J E Health 2011;17:254-261
-
(2011)
Telemed J e Health
, vol.17
, pp. 254-261
-
-
Wakefield, B.J.1
Holman, J.E.2
Ray, A.3
|